Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Acurx PharmaceuticalsFRA:3ZO0 35 Forward Dividend Yield % is 0.00% as of Jul. 27, 2026. GuruFocus rates FRA:3ZO0 with a GF Score™ of 35/100. The stock has 1 warning sign investors should review. Among 149 Biotechnology companies, Acurx Pharmaceuticals ranks worse than 671140.27% on this metric.
As of today (2026-07-27), the Forward Annual Dividend Yield of Acurx Pharmaceuticals is 0.00%.
As of today (2026-07-27), the Trailing Annual Dividend Yield of Acurx Pharmaceuticals is 0.00%.
FRA:3ZO0's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.35 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Acurx Pharmaceuticals Forward Dividend Yield % Related Terms
FRA:3ZO0 vs KAPA, PULM, ADIL: Forward Dividend Yield % Comparison
For the Biotechnology subindustry, Acurx Pharmaceuticals's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acurx Pharmaceuticals Forward Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Acurx Pharmaceuticals's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Acurx Pharmaceuticals's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Acurx Pharmaceuticals (FRA:3ZO0) has a Forward Dividend Yield % of 0.00% as of Jul. 27, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Acurx Pharmaceuticals and its competitors. According to the industry distribution chart, Acurx Pharmaceuticals ranks #999999 out of 149 companies in the Biotechnology industry.
Is Acurx Pharmaceuticals' Forward Dividend Yield % too high?
Acurx Pharmaceuticals' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Acurx Pharmaceuticals ranks #999999 out of 149 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Acurx Pharmaceuticals has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Acurx Pharmaceuticals' Forward Dividend Yield % compare to KAPA and PULM?
According to the Biotechnology industry distribution chart, Acurx Pharmaceuticals ranks #999999 out of 149 companies for Forward Dividend Yield %. This places Acurx Pharmaceuticals in the lower half of its industry. The industry median Forward Dividend Yield % is 1.35. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.35, based on 149 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Acurx Pharmaceuticals and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acurx Pharmaceuticals's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acurx Pharmaceuticals stock overvalued right now?
Acurx Pharmaceuticals (FRA:3ZO0) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Acurx Pharmaceuticals' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Acurx Pharmaceuticals (FRA:3ZO0), the current Forward Dividend Yield % is 0.00% as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
35GF Score
Get the complete analysis for FRA:3ZO0
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3ZO0 has been successfully added to your 
